

IN THE HIGH COURT OF JUSTICE

Case Nos. 258 and 259 of 2017

CHANCERY DIVISION

COMPANIES COURT

(TRANSFERRED FROM THE LIVERPOOL DISTRICT REGISTRY)

REGISTRAR BARBER

22 AUGUST 2017



IN THE MATTER OF REDX PHARMA PLC (IN ADMINISTRATION)

IN THE MATTER OF REDX ONCOLOGY LTD (IN ADMINISTRATION)

AND IN THE MATTER OF THE INSOLVENCY ACT 1986

(1) JASON BAKER

(2) MILES NEEDHAM

(the joint administrators of the above-named companies)

Applicants

---

*Minute of ORDER*

---

**UPON** the two applications of the Applicants, being the joint administrators of Redx Pharma plc ("**Pharma**") and Redx Oncology Ltd (together the "**Companies**"), issued on 17 August 2017 by way of the application notice in the administration of each Company (the "**Applications**")

**UPON** reading the second witness statement of Jason Daniel Baker dated 17 August 2017 ("**Baker-2**")

**AND UPON** hearing Leading Counsel for the Applicants

**IT IS ORDERED THAT:**

1. Pursuant to paragraph 65(3)(b) of Schedule B1 to the Insolvency Act 1986, the Applicants have permission to make distributions to the unsecured creditors of the Companies.
2. In respect of Redx Pharma plc (in administration) only:

- (a) the Joint Administrators shall publish by means of a Regulatory News Service (**RNS**) announcement:
- (i) this Order, as soon as reasonably practicable;
  - (ii) any Progress Report delivered by the Joint Administrators under Rule 18.6 of the Insolvency (England and Wales) Rules 2016, other than a final progress report delivered under Rule 3.55(2), such publication to be made within 1 month of any period covered by such report;
- (b) the Joint Administrators shall respond in like manner as that provided under Rule 18.9(3) to any written request for further information about remuneration and expenses set out in a Progress Report in accordance with rule 18.4(1)(b), (c) or (d) (other than pre-Administration costs) made by:
- (i) a member of Redx Pharma plc (in administration) with at least 5% of the total voting rights of all the members having the right to vote at general meetings of the company;
  - (ii) any other member of Redx Pharma plc (in administration), with the permission of the Court, such permission to be applied for no later than 21 days after the relevant Progress Report has been published by means of an RNS announcement.
3. The costs of this application shall be paid as an expense of the administrations.

*A copy of this Order has been provided to the solicitors for the Applicants (Fieldfisher LLP (c/o Stewart Perry), Riverbank House, 2 Swan Lane, London EC4R 3TT)*

